000027828 000__ 04820cam\a22005535i\4500
000027828 001__ 27828
000027828 003__ SzGeWIPO
000027828 005__ 20230802153826.0
000027828 006__ m\\\\eo\\d\\\\\\\\
000027828 007__ cr bn |||m|||a
000027828 008__ 170306s2011    enk     o|||||||| ||eng d
000027828 020__ $$a9781847316332$$qelectronic book
000027828 020__ $$a9781841139531$$qPrint
000027828 035__ $$aEBL752468
000027828 035__ $$a(OCoLC)746747247
000027828 035__ $$a(wipo)EBL752468
000027828 040__ $$aAU-PeEL$$beng$$erda$$cAU-PeEL$$dCaBNVSL
000027828 041__ $$aeng
000027828 050_4 $$aK1401.A4 1994 Y36 2011
000027828 08204 $$a346.048$$220
000027828 084__ $$aF 630 YAM.I
000027828 1001_ $$aYamane, Hiroko.
000027828 24510 $$aInterpreting TRIPS :$$bGlobalisation of Intellectual Property Rights and Access to Medicines.
000027828 250__ $$aFirst edition.
000027828 264_1 $$aOxford :$$bBloomsbury Publishing,$$c2011.
000027828 300__ $$a582 pages.
000027828 336__ $$atext$$2rdacontent
000027828 337__ $$acomputer$$2rdamedia
000027828 338__ $$aonline resource$$bcr$$2rdacarrier
000027828 500__ $$aDescription based upon print version of record.
000027828 5050_ $$aForeword – Acknowledgements -- Table of Cases -- Table of Legislation -- Introduction -- Part I. Background -- Chapter 1. Innovation Incentives -- Chapter 2. International IP Cooperation and Developing Country Perspectives -- Chapter 3. Biotech Inventions and Patentable Subject Matter -- Part II. The TRIPS Agreement -- Chapter 4. Uruguay Round Negotiations and the Adoption of TRIPS -- Chapter 5. The TRIPS Agreement de Lege Lata: The Outline -- Chapter 6. Various Methods of Interpretation: WTO Agreements and the Vienna Convention on the Law of Treaties -- Chapter 7. TRIPS Provisions as Interpreted by the WTO Dispute Settlement Organs -- Part III. Access to Medicines -- Chapter 8. The AIDS Epidemic and TRIPS -- Chapter 9. Doha Declaration and Beyond -- Part IV. IP and Industrial Policies -- Chapter 10. Emerging Economies’ IP and Industrial Policies -- Chapter 11. Pharmaceutical Industries, R & D and Public Health in Emerging Economies -- Part V. TRIPS Flexibilities and National Implementation -- Chapter 12. TRIPS Flexibilities and National Implementation: (1) Patentable Subject Matter and Patentability Requirements -- Chapter 13. TRIPS Flexibilities and National Implementation: (2) Protection of Test Data Submitted to Regulatory Authorities -- Chapter 14. ‘TRIPS Plus’ Provisions in US Free Trade Agreements -- Part VI. Interpreting TRIPS for Innovation -- Chapter 15. Recasting the Debate on Intellectual Property Rights -- Index
000027828 520__ $$aProtection of intellectual property rights (IPRs) has become a global issue. The Trade-Related Aspects of Intellectual Property (TRIPS) Agreement outlines the minimum standards for IPR protection for WTO members and offers a global regime for IPR protection. However, the benefits of TRIPS are more questionable in poorer countries where national infrastructure for research and development (R & D) and social protection are inadequate, whereas the cost of innovation is high. Today, after more than a decade of intense debate over global IPR protection, the problems remain acute, although there is also evidence of progress and cooperation.  This book examines various views of the role of IPRs as incentives for innovation against the backdrop of development and the transfer of technology between globalised, knowledge-based, high technology economies. The book retraces the origins, content and interpretations of the TRIPS Agreement, including its interpretations by WTO dispute settlement organs. It also analyses sources of controversy over IPRs, examining pharmaceutical industry strategies of emerging countries with different IPR policies.  The continuing international debate over IPRs is examined in depth, as are TRIPS rules and the controversy about implementing the ‘flexibilities’ of the Agreement in the light of national policy objectives. The author concludes that for governments in developing countries, as well as for their business and scientific communities, a great deal depends on domestic policy objectives and their implementation. IPR protection should be supporting domestic policies for innovation and investment. This, in turn requires a re-casting of the debate about TRIPS, to place cooperation in global and efficient R & D at the heart of concerns over IPR protection.
000027828 650_0 $$aPharmaceutical industry$$zDeveloping countries.
000027828 650_0 $$aPatents$$zDeveloping countries.
000027828 650_0 $$aIntellectual property$$zDeveloping countries.
000027828 650_4 $$aPharmaceutical industry -- Developing countries
000027828 650_4 $$aAgreement on Trade-Related Aspects of Intellectual Property Rights (1994)
000027828 650_4 $$aDrugs -- Patents
000027828 650_4 $$aPharmaceutical industry
000027828 650_4 $$aIntellectual property (International law)
000027828 651_0 $$aDeveloping countries$$xCommerce$$xLaw and legislation.
000027828 655_0 $$aElectronic books.
000027828 77608 $$iPrint version:$$aYamane, Hiroko$$tInterpreting TRIPS : Globalisation of Intellectual Property Rights and Access to Medicines$$dOxford : Bloomsbury Publishing,c2011$$z9781841139531
000027828 85641 $$uhttp://ebookcentral.proquest.com/lib/wipo/detail.action?docID=752468$$yView Ebook
000027828 904__ $$aBook
000027828 942__ $$cEBOOK
000027828 980__ $$aBIB
000027828 980__ $$aOS
000027828 999__ $$c30343$$d30343